Biogen and AbbVie have announced the voluntary ... This includes those who experience highly active relapsing MS despite having undergone a full and adequate course of treatment with at least ...
Hosted on MSN1mon
Biogen Stock Declines 21.4% in 3 Months: How to Play the StockBiogen's revenues declined 3% in the first nine months of 2024. Sales of Biogen’s key multiple sclerosis (“MS”) drugs like Tecfidera and Tysabri and spinal muscular atrophy (SMA) treatment ...
In a report released yesterday, Evan Seigerman from BMO Capital maintained a Hold rating on Biogen (BIIB – Research Report), with a price ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback